PATENT CLAIM ANALYSIS

Application Number: 16115973
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-01
Patent Classification: ["424", "450000"]

Abstract:
A process for treating tumors by administering a mixture of cancer fighting drugs incorporated into a stabilized liposomal formulation. Each cancer drug is selected to target a different phase of the cell-cycle of the cancer cell thus expanding the number of cancer cells that can be killed at one time without compromising the safety of the patient. The stabilized multi-drug liposomes are designed to extravasate thru “leaky” blood capillaries supplying the tumor and enter the tumor tissue where they will accumulate over time and ultimately release the mixture of cancer drugs to kill surrounding tumor cells. The multi-drug liposomes are likewise unable to extravasate thru normal blood capillaries and will thus be less toxic to normal tissues.

Claim (Index 17):
The method of  claim 14 , wherein the first cytotoxic drug and the second cytotoxic drug are small molecule drugs that affect cell-division and/or DNA synthesis and function.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 96.0
- Lexical Diversity: 1.5974
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14020592', '14599291', '12891568', '14499201', '11371586']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7585776471749651
- 35 USC 102 Novelty (BERT): 0.5021580095002103
- Combined Prediction Score: 0.7329356834074896
- Mean Citation Score: 216.49398
- Max Citation Score: 224.96416
- Similarity Product: 144.07117631303788

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test